EP1603551A2 - Utilisation d'acides gras omega-3 dans le traitement de personnes diabetiques - Google Patents

Utilisation d'acides gras omega-3 dans le traitement de personnes diabetiques

Info

Publication number
EP1603551A2
EP1603551A2 EP04737282A EP04737282A EP1603551A2 EP 1603551 A2 EP1603551 A2 EP 1603551A2 EP 04737282 A EP04737282 A EP 04737282A EP 04737282 A EP04737282 A EP 04737282A EP 1603551 A2 EP1603551 A2 EP 1603551A2
Authority
EP
European Patent Office
Prior art keywords
dha
epa
diabetes
medicament
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04737282A
Other languages
German (de)
English (en)
Inventor
Rainer Oelze
Cees-Nico Verboom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Products GmbH
Original Assignee
Solvay Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharmaceuticals GmbH filed Critical Solvay Pharmaceuticals GmbH
Priority to EP04737282A priority Critical patent/EP1603551A2/fr
Publication of EP1603551A2 publication Critical patent/EP1603551A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • This invention concerns the use of a pharmaceutical composition containing essential fatty acid ethyl esters originating from fish oils, in particular as a high concentration mixture of ethyl esters of (20:5 ⁇ 3) eicosapentaenoic acid (EPA) and (22:6 ⁇ 3) docosahexaenoic acid (DHA) in patients who suffer from diabetes.
  • EPA eicosapentaenoic acid
  • DHA docosahexaenoic acid
  • the above prior art in particular provide knowledge about the utility of fatty acids belonging to the ⁇ -3 family, more specifically (20:501 3) eicosapentaenoic acid (EPA) and (22:610 3) docosahexaenoic acid (DHA), in treating the above-mentioned disorders.
  • EPA eicosapentaenoic acid
  • DHA docosahexaenoic acid
  • the fatty acid DHA is the most important component of cerebral lip- ids in man and furthermore, being a structural component of the platelet cell it inter- venes indirectly in increasing platelet fluidity, thus playing an important role in antithombotic activity.
  • This invention suggests the novel use of essential fatty acids with a high content in EPA-ethyl ester or DHA-ethyl ester or a high concentration mixture thereof, in the preparation of a medicament useful for the treatment of patients suffering from diabetes.
  • the invention is directed to preventing cardiovascular events in patients who have diabetes mellitus.
  • this invention pertains to the use of essential fatty acids containing a mixture of eicosapentanoic acid ethyl ester (EPA) and docosahexaenoic acid ethyl ester (DHA) in the preparation of a medicament useful for the treatment of patients suffering from diabetes, preferably for preventing cardiovascular events in patients who have diabetes, where the content in EPA and DHA in such mixture is greater than 25% b.w.
  • EPA eicosapentanoic acid ethyl ester
  • DHA docosahexaenoic acid ethyl ester
  • An essential fatty acid with high content in EPA or DHA, according to the present invention preferably contains more than 25% by weight (b.w.), in particular from about 60 to about 100% of such ester.
  • b.w. 25% by weight
  • These compounds can be obtained by known methods.
  • an essential fatty acid with a high concentration mixture of EPA and DHA preferably such mixture has a content in EPA and DHA greater than 25% by weight, in particular from about 30 to about 100% by weight, preferably about 85% by weight.
  • EPA DHA mixture EPA preferably is present in a percentage from about 40 to 60% by weight and DHA, preferably in a percentage from about 25 to about 45-50%. In any case the preferred EPA/DHA ratio in such EPA/DHA mixture is about 0.9/1.5.
  • Diabetes mellitus has become an increasingly prevalent disease worldwide.
  • the prevalence of diabetes is increasing rapidly and the number of individuals with type II diabetes (80-90% of all diabetic people) is depicted to reach 300 million in the year 2025, accounting for 5.4% of the global population.
  • cardiovascular events are important contributors to morbidity and mortality in patients with diabetic disease.
  • the risk of death from cardiovascular disease is in patients with diabetes two to six times that among persons without diabetes.
  • Type II diabetes eliminates the protective advantage of female sex against coronary heart disease mortality.
  • EPA plus DHA induces a reduction in the levels of triglycerides and of very-low density lipoprotein cholesterol (VLDL) in patients with hypertriglyceremia;
  • VLDL very-low density lipoprotein cholesterol
  • the present invention provides a new and valuable therapeutic tool for treating diabetic patients, and in particular for preventing cardiovascular events in diabetic patients.
  • this invention also provides a method for treating diabetic patients, preferably patients with diabetes mellitus and in particular for preventing cardiovascular events in diabetic patients, preferably in patients with diabetes mellitus, comprising administering to such patient a therapeutically effective amount of a medicament containing essential fatty acids with a high content in EPA-ethyl ester or DHA-ethyl ester or a high concentration mixture thereof.
  • the essential fatty acids can either have a high content, for instance more than 25% b.w., in EPA or DHA or in a mixture thereof.
  • EPA and DHA-ethyl ester are preferably present as a mixture thereof with a content in EPA and DHA higher than 25% b.w., in particular from about 30 to about 100% b.w., preferably about 85% b.w.
  • the dosage of an essential fatty acid containing an EPA and DHA mixture with 85% b.w. titer for oral administration to a patient may vary from about 0.7g to about 6g daily, preferably about 1g daily.
  • This amount of product as EPA and DHA mixture may be administered in several divided doses throughout the day or preferably in a single administration, in order to achieve the desired hematic level. Obviously it is at the discretion of the physician to adjust the quantity of product to be administered according to the age, weight and general conditions of the patient.
  • the medicament e.g. in the form of a pharmaceutical composition, according to this invention can be prepared according to known methods in the art.
  • the preferred route of administration is the oral one, however leaving alternative routes of administration, such as the parenteral route, to the discretion of the physician.
  • capsules having the composition below and containing 1g of active ingredient (EPA and DHA, 85% titer) per capsule are prepared.

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne l'utilisation d'acides gras essentiels à teneur élevée en ester d'éthyle d'acide eicosapentanoïque (EPA) ou un ester d'éthyle d'acide docosahexanoïque (DHA), lesdits acides gras étant utilisés pour prévenir des événements cardio-vasculaires chez des patients souffrant de diabète sucré.
EP04737282A 2003-03-05 2004-03-02 Utilisation d'acides gras omega-3 dans le traitement de personnes diabetiques Withdrawn EP1603551A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP04737282A EP1603551A2 (fr) 2003-03-05 2004-03-02 Utilisation d'acides gras omega-3 dans le traitement de personnes diabetiques

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP03004792 2003-03-05
EP03004792 2003-03-05
PCT/EP2004/050238 WO2004078166A2 (fr) 2003-03-05 2004-03-02 Utilisation d'acides gras omega-3 dans le traitement de personnes diabetiques
EP04737282A EP1603551A2 (fr) 2003-03-05 2004-03-02 Utilisation d'acides gras omega-3 dans le traitement de personnes diabetiques

Publications (1)

Publication Number Publication Date
EP1603551A2 true EP1603551A2 (fr) 2005-12-14

Family

ID=32946844

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04737282A Withdrawn EP1603551A2 (fr) 2003-03-05 2004-03-02 Utilisation d'acides gras omega-3 dans le traitement de personnes diabetiques

Country Status (8)

Country Link
EP (1) EP1603551A2 (fr)
JP (1) JP2006519244A (fr)
CN (1) CN1756545A (fr)
AU (1) AU2004216856A1 (fr)
BR (1) BRPI0408006A (fr)
CA (1) CA2515328A1 (fr)
MX (1) MXPA05009432A (fr)
WO (1) WO2004078166A2 (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9901809D0 (en) 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
WO2006073147A1 (fr) * 2005-01-04 2006-07-13 Mochida Pharmaceutical Co., Ltd. Agent thérapeutique contre la toxicité des graisses
CN101213281B (zh) * 2005-05-04 2013-03-13 普罗诺瓦生物医药挪威公司 新的dha衍生物及其作为药物的用途
KR101255650B1 (ko) * 2005-05-04 2013-04-16 프로노바 바이오파마 너지 에이에스 새로운 ｄｈａ 유도체 및 약제로서의 용도
JP2008540394A (ja) 2005-05-04 2008-11-20 プロノヴァ バイオファーマ ノルゲ アクティーゼルスカブ 脂肪酸組成物、即ち、ｄｈａ誘導体の医薬としての使用
JP5134916B2 (ja) * 2005-07-08 2013-01-30 持田製薬株式会社 心血管イベント発症予防用組成物
KR101465715B1 (ko) * 2005-07-08 2014-11-27 모치다 세이야쿠 가부시키가이샤 심혈관 이벤트 발병 예방용 조성물
BRPI0717972A2 (pt) * 2006-11-01 2013-11-12 Pronova Biopharma Norge As Lipídeos de ômega-3 alfa-substituídos que são ativadores ou moduladores do receptor ativado por proliferadores de peroxissoma (ppar)
WO2008142482A2 (fr) * 2006-11-01 2008-11-27 Pronova Biopharma Norge As Composition
US8399516B2 (en) 2006-11-01 2013-03-19 Pronova Biopharma Norge As Alpha-substituted omega-3 lipids that are activators or modulators of the peroxisome proliferators-activated receptor (PPAR)
CN101646426A (zh) * 2006-11-03 2010-02-10 普罗诺瓦生物医药挪威公司 ω-3脂质化合物
WO2010018856A1 (fr) * 2008-08-13 2010-02-18 持田製薬株式会社 Agent prophylactique/d’amélioration ou thérapeutique destiné aux maladies associées au récepteur des cannabinoïdes
PL2334295T3 (pl) 2008-09-02 2017-12-29 Amarin Pharmaceuticals Ltd Kompozycja farmaceutyczna zawierająca kwas eikozapentaenowy i kwas nikotynowy oraz sposoby jej zastosowania
SI3037089T1 (sl) 2009-02-10 2020-03-31 Amarin Pharmaceuticals Ireland Limited, Etilester eikozapentaenojske kisline za zdravljenje hipertrigliceridemije
EP3797591A1 (fr) 2009-04-29 2021-03-31 Amarin Pharmaceuticals Ireland Limited Composition pharmaceutique stable et procédés d'utilisation associés
BRPI1014405A2 (pt) 2009-04-29 2016-04-05 Amarin Corp Plc composições farmacêuticas compreendendo epa e um agente cardiovascular e métodos de seu uso
KR20120016677A (ko) 2009-06-15 2012-02-24 아마린 파마, 인크. 병용 스타틴 요법을 받는 대상체에서 ｌｄｌ－ｃ 수준을 상승시키지 않으면서 트리글리세리드를 저하시키기 위한 조성물 및 방법
FR2949063B1 (fr) * 2009-08-11 2011-09-30 Pf Medicament Composition pharmaceutique comprenant un ester de dha destinee a etre administree par voie parenterale
SG10201405994UA (en) 2009-09-23 2014-10-30 Amarin Pharmaceuticals Ie Ltd Pharmaceutical Composition Comprising Omega-3 Fatty Acid And Hydroxy-derivative Of A Statin And Methods Of Using Same
CN103338762B (zh) * 2010-11-09 2015-03-25 持田制药株式会社 血糖值上升抑制剂
NZ712068A (en) 2010-11-29 2017-03-31 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
EP2775837A4 (fr) 2011-11-07 2015-10-28 Amarin Pharmaceuticals Ie Ltd Méthodes de traitement de l'hypertriglycéridémie
ES2891473T3 (es) 2012-01-06 2022-01-28 Amarin Pharmaceuticals Ie Ltd Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto
HUE053111T2 (hu) 2012-06-29 2021-06-28 Amarin Pharmaceuticals Ie Ltd Módszerek kardiovaszkuláris események veszélyének csökkentésére sztatin terápiával kezelt alanyban eikozapentaénsav-etilészter alkalmazásával
WO2014074552A2 (fr) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions et procédés pour diminuer les triglycérides sans augmenter les taux de ldl-c chez un sujet traité en même temps par la statine
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (fr) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Procédés de réduction ou de prévention de l'oxydation des ldl petites et denses ou des acides gras polyinsaturés membranaires
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
WO2018213663A1 (fr) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions et méthodes pour dimunuer les triglycérides chez un sujet ayant une fonction rénale réduite
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
PT4056176T (pt) 2018-09-24 2024-05-27 Amarin Pharmaceuticals Ie Ltd Métodos de redução do risco de eventos cardiovasculares num indivíduo
WO2022225896A1 (fr) 2021-04-21 2022-10-27 Amarin Pharmaceuticals Ireland Limited Procédés de réduction du risque d'insuffisance cardiaque

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60248610A (ja) * 1984-05-23 1985-12-09 Nitsusui Seiyaku Kk 糖尿病合併症の予防および治療剤
GB2218904A (en) * 1988-05-27 1989-11-29 Renafield Limited Pharmaceutical composition based on high-concentration esters of docosahexaenoic acid
GB2223943A (en) * 1988-10-21 1990-04-25 Tillotts Pharma Ag Oral disage forms of omega-3 polyunsaturated acids

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2004078166A2 *

Also Published As

Publication number Publication date
WO2004078166A3 (fr) 2004-10-28
BRPI0408006A (pt) 2006-02-14
MXPA05009432A (es) 2005-11-23
JP2006519244A (ja) 2006-08-24
CN1756545A (zh) 2006-04-05
WO2004078166A2 (fr) 2004-09-16
AU2004216856A1 (en) 2004-09-16
CA2515328A1 (fr) 2004-09-16

Similar Documents

Publication Publication Date Title
EP1603551A2 (fr) Utilisation d'acides gras omega-3 dans le traitement de personnes diabetiques
EP1152755B1 (fr) Acides gras essentiels destines a la prevention d'accidents cardio-vasculaires
Kojima et al. Long-term administration of highly purified eicosapentaenoic acid provides improvement of psoriasis
KR101336756B1 (ko) 뇌졸중 재발 예방용 조성물
US7439267B2 (en) Essential n-3 fatty acids in cardiac insufficiency and heart failure therapy
JP2004534800A (ja) 心臓血管疾患、関節炎、皮膚ガン、糖尿病、月経前症候群および経皮送達の予防および／または治療のためのオキアミおよび／または海洋生物の抽出物
US20040235948A1 (en) Treatment of diabetic patients with omega-3-fatty acids
AU2018229440A1 (en) Administering compositions comprising docosapentaenoic acid
US8114906B2 (en) Essential fatty acids in the treatment and/or inhibition of depression in patients with coronary heart or artery disease
AU2005244483B2 (en) Essential fatty acids in the prevention and/or treatment of depression in patients with coronary heart or artery disease
JP2007532605A5 (fr)
MXPA01008213A (en) Essential fatty acids in the prevention of cardiovascular events

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20051005

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

RAX Requested extension states of the european patent have changed

Extension state: LV

Payment date: 20051005

Extension state: LT

Payment date: 20051005

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060620